[1]
Halliwell, B. Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? The Lancet, 1994, 344, 721-724.
[2]
Langseth, L. From the editor: Antioxidants and diseases of the brain. Antioxidant Vit. Newslett, 1993, 4
[3]
Kalam, S.; Gul, M.Z.; Singh, R.; Ankati, S. Free radicals: Implications in etiology of chronic diseases and their amelioration through nutraceuticals. Pharmacologia, 2015, 6, 11-20.
[4]
Lü, J-M.; Lin, P.H.; Yao, Q.; Chen, C. Chemical and molecular mechanisms of antioxidants: Experimental approaches and model systems. J. Cell. Mol. Med., 2010, 14, 840-860.
[5]
Shen, X.; Saburi, W.; Gai, Z.; Kato, K.; Ojima-Kato, T.; Yu, J.; Komoda, K.; Kido, Y.; Matsui, H.; Mori, H. Structural analysis of the α-glucosidase hag provides new insights into substrate specificity and catalytic mechanism. Acta Crystallogr. Sect D Biol. Crystallogr., 2015, 71, 1382-1391.
[6]
Jacob, R.A. The integrated antioxidant system. Nutr. Res., 1995, 15, 755-766.
[7]
Fujita, K.; Miyamura, T.; Sano, M.; Kato, I.; Takegawa, K. Transfer of high-mannose-type oligosaccharides to disaccharides by endo-β-n-acetylglucosaminidase from arthrobacter protophormiae. J. Biosci. Bioeng., 2002, 93, 614-617.
[8]
Balbaa, M.; Shibli, A.; Hosna, R.; Yusef, H.; Ahmed, T.A.B.; El Ashry, E.S.H. Biological effect of glycosyl-oxadiazolinethione and glycosyl-sulfanyloxadiazole derivatives through their in vitro inhibition of glycosidases from bacteria and normal or diabetic rats. Lett. Drug Des. Discov., 2015, 12, 211-218.
[9]
Stauffert, F.; Bodlenner, A.; Trinh, T.M.N.; García-Moreno, M.I.; Mellet, C.O.; Nierengarten, J-F.; Compain, P. Understanding multivalent effects in glycosidase inhibition using C-glycoside click clusters as molecular probes. New J. Chem., 2016, 40, 7421-7430.
[10]
Balbaa, M.; Mansour, H.; El-Sawy, H.; El-Ashry, E.S.H. Inhibition of some hepatic glycosidases by the diseco nucleoside, 4-amino-3-(d-glucopentitol-1-yl)-5-mercapto-1, 2, 4-triazole and its 3-methyl analog. Nucleosides. Nucl. Nucl. Acids, 2002, 21, 695-708.
[11]
Chiba, S. Molecular mechanism in α-glucosidase and glucoamylase. Biosci. Biotechnol. Biochem., 1997, 61, 1233-1239.
[12]
Khan, K.M.; Rahim, F.; Halim, S.A.; Taha, M.; Khan, M.; Perveen, S.; Mesaik, M.A.; Choudhary, M.I. Synthesis of novel inhibitors of β-glucuronidase based on benzothiazole skeleton and study of their binding affinity by molecular docking. Bioorg. Med. Chem., 2011, 19, 4286-4294.
[13]
Sperker, B.; Backman, J.T.; Kroemer, H.K. The role of β-glucuronidase in drug disposition and drug targeting in humans. Clin. Pharmacokinet., 1997, 33, 18-31.
[14]
Kim, D-H.; Jin, Y-H. Intestinal bacterial β-glucuronidase activity of patients with colon cancer. Arch. Pharm. Res., 2001, 24, 564-567.
[15]
Cheng, T.C.; Roffler, S.R.; Tzou, S.C.; Chuang, K-H.; Su, Y.C.; Chuang, C.H.; Kao, C.H.; Chen, C.S.; Harn, I.H.; Liu, K.Y. An activity-based near-infrared glucuronide trapping probe for imaging β-glucuronidase expression in deep tissues. J. Am. Chem. Soc., 2012, 134, 3103-3110.
[16]
Juan, T.Y.; Roffler, S.R.; Hou, H-S.; Huang, S-M.; Chen, K.C.; Leu, Y.L.; Prijovich, Z.M.; Yu, C.P.; Wu, C.C.; Sun, G-H. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity. Clin. Cancer Res., 2009, 15, 4600-4611.
[17]
Baharudin, M.S.; Taha, M.; Imran, S.; Ismail, N.H.; Rahim, F.; Javid, M.T.; Khan, K.M.; Ali, M. Synthesis of indole analogs as potent β-glucuronidase inhibitors. Bioorg. Chem., 2017, 72, 323-332.
[18]
Balbaa, M.; Abdel-Hady, N.; El-Rashidy, F.; Awad, L.; El-Ashry, E-S.H.; Schmidt, R.R. Inhibition of some hepatic lysosomal glycosidases by ethanolamines and phenyl 6-deoxy-6-(morpholin-4-yl)-β-d-glucopyranoside. Carbohydr. Res., 1999, 317, 100-109.
[19]
Gong, Z.; Peng, Y.; Qiu, J.; Cao, A.; Wang, G.; Peng, Z. Synthesis, in vitro α-glucosidase inhibitory activity and molecular docking studies of novel benzothiazole-triazole derivatives. Molecules, 2017, 22, 1555-1565.
[20]
Gerber-Lemaire, S.; Juillerat-Jeanneret, L. Glycosylation pathways as drug targets for cancer: Glycosidase inhibitors. Mini Rev. Med. Chem., 2006, 6, 1043-1052.
[21]
de Melo, E.B.; da Silveira, G.A.; Carvalho, I. A-and β-glucosidase inhibitors: Chemical structure and biological activity. Tetrahedron, 2006, 62, 10277-10302.
[22]
Asano, N. Glycosidase inhibitors: Update and perspectives on practical use. Glycobiology, 2003, 13, 93R-104R.
[23]
Vocadlo, D.J.; Hang, H.C.; Kim, E-J.; Hanover, J.A.; Bertozzi, C.R. A chemical approach for identifying O-GLcNAc-modified proteins in cells. Proc. Natl. Acad. Sci., 2003, 100, 9116-9121.
[24]
Rani, M.; Sharma, S.; Chauhan, R.; Sharma, S.; Dwivedi, J. Synthesis, characterization and antibacterial evaluation of some azole derivatives. Ind. J. Pharm. Edu. Res., 2017, 51, 650-655.
[25]
Chawla, G.; Naaz, B.; Siddiqui, A.A. Exploring 1, 3, 4-oxadiazole scaffold for anti-inflammatory and analgesic activities: A review of literature from 2005-2016. Mini Rev. Med. Chem., 2018, 18, 216-233.
[27]
Aouad, M.R.; Mayaba, M.M.; Naqvi, A.; Sanaa, K. Bardaweel, S.K.; Al‑blewi, F.F.; Messali, M.; Rezki, N. Design, synthesis, ex silico and in vitro antimicrobial screenings of novel 1,2,4‑triazoles carrying 1,2,3‑triazole scaffold with lipophilic side chain tether. Chem. Cent. J., 2017, 11, 117-129.
[28]
Siddiqui, S.M.; Salahuddin, A.; Azam, A. Synthesis, characterization and antiamoebic activity of some hydrazone and azole derivatives bearing pyridyl moiety as a promising heterocyclic scaffold. Eur. J. Med. Chem., 2012, 49, 411-416.
[29]
Hou, Z.; Nakanishi, I.; Kinoshita, T.; Takei, Y.; Yasue, M.; Misu, R.; Suzuki, Y.; Nakamura, S.; Kure, T.; Ohno, H. Structure-based design of novel potent protein kinase ck2 (ck2) inhibitors with phenyl-azole scaffolds. J. Med. Chem., 2012, 55, 2899-2903.
[30]
El‐Ashry, E.S.H.; El Nemr, A. Synthesis of naturally occurring nitrogen heterocycles from carbohydrates; John Wiley & Sons, 2008.
[31]
He, X-P.; Zeng, Y-L.; Zang, Y.; Li, J.; Field, R.A.; Chen, G-R. Carbohydrate CuAAC click chemistry for therapy and diagnosis. Carbohydr. Res., 2016, 429, 1-22.
[32]
El‐Ashry, E.S.H.; Rashed, N.; Awad, L.F.; Ramadan, E.S.
Abdel‐Maggeed, S.M.; Rezki, N. Synthesis of 5‐aryl‐3‐glycosylthio‐4‐phenyl‐4h‐1, 2, 4‐triazoles and their acyclic analogs under conventional and microwave conditions. J. Carbohydr. Chem., 2008, 27, 70-85.
[33]
Rezki, N.; Rashed, N.; Awad, L.; Ramadan, E.; Abdel-Maggeed, S.; El‐Ashry, E.S.H. Regio-and stereoselective synthesis of thioglycosides from 4, 5-diphenyl-and 3, 4, 5-triphenylimidazole-2-thione. Phosph. Sulfur Silicon, 2009, 184, 1759-1767.
[34]
Randhawa, M.A. Calculation of LD50 values from the method of miller and tainter, 1944. J. Ayub Med. Coll. Abbottabad, 2009, 21, 184-185.
[36]
Salahuddin, K.; Prasad, R.; Kumar, S.; Visavadia, M.D. Isolation of soil thermophilic strains of actinomycetes for the production of α-amylase. Afr. J. Biotechnol., 2011, 10, 17831-17236.
[37]
Sutherland, M.W.; Learmonth, B.A. The tetrazolium dyes mts and xtt provide new quantitative assays for superoxide and superoxide dismutase. Free Radic. Res., 1997, 27, 283-289.
[38]
Habig, W.H.; Pabst, M.J.; Jakoby, W.B. Glutathione s-transferases the first enzymatic step in mercapturic acid formation. J. Biol. Chem., 1974, 249, 7130-7139.
[39]
Paglia, D.E.; Valentine, W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med., 1967, 70, 158-169.
[40]
Aebi, H. Catalase in vitro. In: Methods Enzymol., 105. Elsevier,
(1984):121-126.
[41]
Tappel, A.; Zalkin, H. Lipide peroxidation in isolated mitochondria. Arch. Biochem. Biophys., 1959, 80, 326-332.
[42]
Balba, M.; El-Hady, N.A.; Taha, N.; Rezki, N.; El‐Ashry, E.S.H. Inhibition of α-glucosidase and α-amylase by diaryl derivatives of imidazole-thione and 1, 2, 4-triazole-thiol. Eur. J. Med. Chem., 2011, 46, 2596-2601.
[43]
Dowd, J.E.; Riggs, D.S. A comparison of estimates of Michaelis-Menten kinetic constants from various linear transformations. J. Biol. Chem., 1965, 240, 863-869.
[44]
Gornall, A.G.; Bardawill, C.J.; David, M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem., 1949, 177, 751-766.
[45]
Molecular Operating Environment (MOE), 2013.08; Chemical Computing
Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal,
QC, Canada, H3A 2R7, , 2018.
[46]
Michikawa, M.; Ichinose, H.; Momma, M.; Biely, P.; Jongkees, S.; Yoshida, M.; Kotake, T.; Tsumuraya, Y.; Withers, S.G.; Fujimoto, Z. Structural and biochemical characterization of glycoside hydrolase family 79 β-glucuronidase from acidobacterium capsulatum. J. Biol. Chem., 2012, 287, 14069-14077.
[47]
Halgren, T.A. Mmff vi. Mmff94s option for energy minimization studies. J. Comput. Chem., 1999, 20, 720-729.
[48]
Vilar, S.; Cozza, G.; Moro, S. Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery. Curr. Top. Med. Chem., 2008, 8, 1555-1572.
[49]
Labute, P. Protonate 3d: Assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins: Structure, Func. Bioinf., 2009, 75, 187-205.
[50]
Goto, J.; Kataoka, R.; Muta, H.; Hirayama, N. Asedock-docking based on alpha spheres and excluded volumes. J. Chem. Inf. Model., 2008, 48, 583-590.
[51]
Hansch, C.; Fujita, T. P-σ-π analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc., 1964, 86, 1616-1626.
[52]
Dassault Systèmes, BIOVIA Discovery Studio Modeling Environment, Release 2017; San Diego: Dassault Systèmes, 2016.
[53]
De Oliveira, D.B.; Gaudio, A.C. Buildqsar: A new computer program for QSAR analysis. Quant Struct.-. Activ. Relat., 2001, 19, 599-601.
[54]
Gramatica, P. Principles of qsar models validation: Internal and external. QSAR & Combinatorial Sci, 2007, 26, 694-701.
[55]
Alexander, D.; Tropsha, A.; Winkler, D.A. Beware of r2: Simple, unambiguous assessment of the prediction accuracy of QSAR and QSPR models. J. Chem. Inf. Model., 2015, 55, 1316-1322.
[56]
Al-Ali, A.; Alkhawajah, A.A.; Randhawa, M.A.; Shaikh, N.A. Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats. J. Ayub Med. Coll. Abbottabad, 2008, 20, 25-27.
[57]
Grodnitzky, J.A.; Coats, J.R. Qsar evaluation of monoterpenoids’ insecticidal activity. J. Agric. Food Chem., 2002, 50, 4576-4580.
[58]
Chang, H.J.; Kim, H.J.; Chun, H.S. Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids. Life Sci., 2007, 80, 835-841.
[59]
Tong, F.; Coats, J.R. Quantitative structure-activity relationships of monoterpenoid binding activities to the housefly GABA receptor. Manage. Sci., 2012, 68, 1122-1129.
[60]
Kumar, P.; Narasimhan, B.; Sharma, D.; Judge, V.; Narang, R. Hansch analysis of substituted benzoic acid benzylidene/furan-2-yl-methylene hydrazides as antimicrobial agents. Eur. J. Med. Chem., 2009, 44, 1853-1863.
[61]
Takayama, C.; Fujinami, A. Quantitative structure-activity relationships of antifungal n-phenylsuccinimides and n-phenyl-1, 2-dimethylcyclopropanedicarboximides. Pestic. Biochem. Physiol., 1979, 12, 163-171.
[62]
da Rocha, D.R.; Santos, W.C.; Lima, E.S.; Ferreira, V.F. Synthesis of 1, 2, 3-triazole glycoconjugates as inhibitors of α-glucosidases. Carbohydr. Res., 2012, 350, 14-19.
[63]
Ellmers, B.R.; Rhinehart, B.L.; Robinson, K.M. Castanospermine: An apparent tight-binding inhibitor of hepatic lysosomal alpha-glucosidase. Biochem. Pharmacol., 1987, 36, 2381-2385.
[64]
Berg, J.M.; Tymoczko, J.; Gatto, J.G. Stryer: Biochemistry. WH Freeman and Company., 2002, 5, 306-307.
[65]
Hughes, A.; Rudge, A. Deoxynojirimycin: Synthesis and biological activity. Nat. Prod. Rep., 1994, 11, 135-162.
[66]
Poláková, M.; Stanton, R.; Wilson, I.B.H.; Holková, I.; Šesták, S.; Machová, E.; Jandová, Z.; Kóňa, J. Click chemistry synthesis of 1-(α-D-mannopyranosyl)-1,2,3-triazoles for inhibition of α-mannosidases. Carbohydr. Res., 2015, 406, 34-40.
[67]
Onodera, S.; Matsui, H.; Chiba, S. Single active site mechanism of rabbit liver acid α-glucosidase. The J. Biochem., 1989, 105, 611-618.
[68]
Chiba, S. A historical perspective for the catalytic reaction mechanism of glycosidase; so as to bring about breakthrough in confusing situation. Biosci. Biotechnol. Biochem., 2012, 76, 215-231.
[69]
Yoshimizu, M.; Tajima, Y.; Matsuzawa, F.; Aikawa, S.I.; Iwamoto, K.; Kobayashi, T.; Edmunds, T.; Fujishima, K.; Tsuji, D.; Itoh, K. Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid α-glucosidase (alglucosidase alfa): Insight into the complex formation mechanism. Clin. Chim. Acta, 2008, 391, 68-73.
[70]
Smesh, S.; Madhuri, K. Triazolyl glycoconjugates and their impact in medicinal chemistry. Org. Chem. Ind. J., 2016, 12, 104-125.
[71]
Sorrenti, V.; Salerno, L.; Di Giacomo, C.; Acquaviva, R.; Siracusa, M.; Vanella, A. Imidazole derivatives as antioxidants and selective inhibitors of nnos. Nitric Oxide, 2006, 14, 45-50.
[72]
Naik, N.; Kumar, H.V.; Rangaswamy, J.; Harini, S.T.; Umeshkumar, T.C. Three component one pot synthesis of 5-Substituted 1-Aryl-2,3-diphenyl imidazoles: A novel class of promising antioxidants. J. Appl. Pharm. Sci., 2012, 2, 67-74.
[73]
Singh, P.; Kumar, R.; Tiwari, S.; Khanna, R.S.; Tewari, A.K.; Khanna, H.D. Docking, synthesis and evaluation of antioxidant activity of 2,4,5-triaryl imidazole. Clin. Med. Biochemistry, 2015, 1, 1-4.
[74]
Charles, E.O. Molecular Polarity. In: virtual chembook, Elmhurst
college, 2003.
[75]
Kuramitsu, Y.; Hamada, J.I.; Tsuruoka, T.; Morikawa, K.; Kobayashi, H.; Hosokawa, M. A new anti-metastatic drug, ND-2001, inhibits lung metastases in rat hepatoma cells by suppressing haptotaxis of tumor cells toward laminin. Anticancer Drugs, 1998, 9, 88-92.
[76]
Michiels, C.; Remacle, J. Use of the inhibition of enzymatic antioxidant systems in order to evaluate their physiological importance. FEBS J., 1988, 177, 435-441.
[77]
Ekinci, D.; Cankaya, M.; Gül, İ.; Coban, T.A. Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione s-transferase to different antibiotics: In vitro approach. J. Enzyme Inhib. Med. Chem., 2013, 28, 824-829.
